阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的现状  

Current status of atezolizumab combined with bevacizumab in the treatment of hepatocellular carcinoma

作　　者：郭亚明 朱兴[2] 戴朝六[1] 徐锋[1] Guo Yaming;Zhu Xing;Dai Chaoliu;Xu Feng(Department of General Surgery,Shengjing Hospital of China Medical University,Shenyang 110004,China;Department of Hepatobiliary Surgery,Shenyang Fourth People's Hospital,Shenyang 110031,China)

机构地区：[1]中国医科大学附属盛京医院普通外科,沈阳110004 [2]沈阳市第四人民医院肝胆外科,沈阳110031

出　　处：《中华肝胆外科杂志》2022年第10期789-792,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：辽宁省自然科学基金项目(20180551193、2020-MS-181);盛京医院345人才工程计划(40B)。

摘　　要：肝细胞癌(简称肝癌)起病隐匿,病情进展迅速,多数患者发现时已丧失手术机会,系统治疗效果并不理想。近年来免疫检查点抑制剂联合靶向药物治疗的兴起给肝癌患者带来了希望,尤其是阿替利珠单抗+贝伐珠单抗治疗方案已被国内外多个指南推荐作为既往未接受过系统治疗的不可切除肝癌的一线治疗方案。本文从阿替利珠单抗+贝伐珠单抗治疗方案的应用现状、治疗失效后的应对策略、成本-效益分析以及不良反应四个方面进行阐述,以期为临床治疗提供参考。Hepatocellular carcinoma(HCC)has a hidden onset and rapid progress.Most of the patients have lost the opportunity of surgery at the onset,and the systemic treatment effect is not satisfactory.In recent years,immune checkpoint inhibitors combined with targeted therapy have brought hope to HCC patients.In particular,treatment with atezolizumab combined with bevacizumab has been recommended by many domestic and foreign guidelines as the first-line treatment for patients with unresectable HCC who have not previously received systematic treatment.In this review,the application status of atezolizumab plus bevacizumab,coping strategies for treatment failure,cost-benefit analysis and side effects were described in order to provide reference for clinical treatment.

关 键 词：癌 肝细胞 阿替利珠单抗 贝伐珠单抗 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]